Daily Market Reports | Dec 24 2025
This story features AMAERO LIMITED, and other companies.
For more info SHARE ANALYSIS: 3DA
The company is included in ALL-ORDS
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely “regularly” depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena’s team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
3DA ACW AHL ARF ATA AZY BGL BOE MPW NWL PLY PWR SGLLV TLX
3DA AMAERO LIMITED
Industrial Sector Contractors & Engineers – Overnight Price: $0.25
Research as a Service (RaaS) rates ((3DA)) as No Rating (-1) –
Amaero announced it has received a $4.6m order from Titomic ((TTT)) for refractory alloy powders, with shipments expected across 3Q and 4Q26.
The order, as explained by the analyst, is under the previously announced five year exclusive supplier and development agreement between the two companies.
Valuation 82c.
Research as a Service (RaaS) research standard doesn’t carry any targets, ratings or recommendations. Investors can draw conclusions from valuations and commentary.
This report was published on December 22, 2025.
Target price is $0.82 Current Price is $0.25 Difference: $0.57
If 3DA meets the Research as a Service (RaaS) target it will return approximately 228% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Research as a Service (RaaS) forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 2.40 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 10.42.
Forecast for FY27:
Research as a Service (RaaS) forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 0.90 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 27.78.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ACW ACTINOGEN MEDICAL LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $0.06
Canaccord Genuity rates ((ACW)) as Speculative Buy (1) –
Canaccord Genuity retains a Speculative Buy rating and 8c target price on Actinogen Medical, with the biotech closing enrollment at 246 participants for the randomised, double blind, placebo controlled phase 2b/3 trial (XanaMIA).
The readout is due in November 2026 and a positive result should pave the way for a final phase 3 trial, the analyst notes.
An interim analysis of safety and efficacy is anticipated in late January.
This report was published on December 18, 2025.
Target price is $0.08 Current Price is $0.06 Difference: $0.021
If ACW meets the Canaccord Genuity target it will return approximately 36% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 1.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 5.90.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
AHL ADRAD HOLDINGS LIMITED
Overnight Price: $1.02
Taylor Collison rates ((AHL)) as Initiation of coverage with Buy (1) –
Taylor Collison has initiated coverage of Adrad with a Buy rating and target price of $1.35.
The company designs and manufactures heat-exchange/cooling systems for transport, industrial and mining customers, with growing exposure to data centres and electrification.
The broker notes the core business is profitable with strong returns and scope for volume and margin upside. New management is pushing to convert Asia, distribution and product initiatives into growth.
Despite liquidity and CEO succession risks, the stock is materially undervalued, in the broker’s opinion, supported by a strong order book and over 20% of trailing EBITDA in cost savings.
This report was published on December 16, 2025.
Target price is $1.35 Current Price is $1.02 Difference: $0.33
If AHL meets the Taylor Collison target it will return approximately 32% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Taylor Collison forecasts a full year FY26 dividend of 4.10 cents and EPS of 9.10 cents.
At the last closing share price the estimated dividend yield is 4.02%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 11.21.
Forecast for FY27:
Taylor Collison forecasts a full year FY27 dividend of 5.30 cents and EPS of 10.60 cents.
At the last closing share price the estimated dividend yield is 5.20%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.62.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ARF ARENA REIT
REITs – Overnight Price: $3.69
Moelis rates ((ARF)) as Buy (1) –
Moelis notes 1H26 childcare valuations were up 3.6%, with an average cap rate tightening 9bps to 5.32%.
Healthcare valuations rose slightly by 0.3%, with a rise of 3bps in the cap rate, while Arena REIT’s overall portfolio valuation grew by 3.3%.
Average rents rose 3.6% over 1H26 on a like for like basis, with CPI linked leases boosted by 12 market rent reviews with an average 7.6% increase, the analyst states.
Maintain Buy rating and $4.09 target price.
This report was published on December 19, 2025.
Target price is $4.09 Current Price is $3.69 Difference: $0.4
If ARF meets the Moelis target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $4.19, suggesting upside of 13.6%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 19.30 cents and EPS of 19.60 cents.
At the last closing share price the estimated dividend yield is 5.23%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.83.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 19.7, implying annual growth of -5.7%.
Current consensus DPS estimate is 19.3, implying a prospective dividend yield of 5.2%.
Current consensus EPS estimate suggests the PER is 18.7.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 20.20 cents and EPS of 20.50 cents.
At the last closing share price the estimated dividend yield is 5.47%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.00.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 20.3, implying annual growth of 3.0%.
Current consensus DPS estimate is 20.2, implying a prospective dividend yield of 5.5%.
Current consensus EPS estimate suggests the PER is 18.2.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ATA ATTURRA LIMITED
Software & Services – Overnight Price: $0.66
Moelis rates ((ATA)) as Buy (1) –
Atturra announced a subsidiary of the company received a termination notice for a fixed term contract with an Australian public sector body, Moelis explains, and the company is currently assessing its legal options, with the aim of disputing the “purported” wrongful termination.
Management has updated revenue guidance to $364-$374m from $384m-plus previously and underlying earnings (EBITDA) of $30m-$41m from $40.3m-plus previously, with 1H26 around $7m and 2H26 circa $23-$24m.
The analyst lowers EPS forecasts to account for the contract termination by -39.3% for FY26 and -11.9% for FY27.
The target price falls to 83c from $1.06 previously, with the Buy rating retained.
This report was published on December 19, 2025.
Target price is $0.83 Current Price is $0.66 Difference: $0.17
If ATA meets the Moelis target it will return approximately 26% (excluding dividends, fees and charges).
Current consensus price target is $1.07, suggesting upside of 61.6%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 3.50 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.86.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 5.9, implying annual growth of 126.9%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 11.2.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 0.00 cents and EPS of 6.20 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 10.65.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 6.3, implying annual growth of 6.8%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 10.5.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
AZY ANTIPA MINERALS LIMITED
Mining – Overnight Price: $0.59
Canaccord Genuity rates ((AZY)) as Speculative Buy (1) –
Antipa Minerals announced a 6% lift in its resources for the 100% owned Minyari project, which supports the view of a large scale, possibly stand alone gold-copper project opportunity, according to Canaccord Genuity.
The latest resource, including satellites, sits at a reported 3.3Moz AuEq, made up of 2.7Moz Au and 90kt Cu, with the analyst highlighting total resource growth over 2025 at 263koz Au and 6kt Cu, or around 400koz AuEq.
Speculative Buy maintained. Target price remains at $1.20.
This report was published on December 18, 2025.
Target price is $1.20 Current Price is $0.59 Difference: $0.605
If AZY meets the Canaccord Genuity target it will return approximately 102% (excluding dividends, fees and charges).
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
BGL BELLEVUE GOLD LIMITED
Gold & Silver – Overnight Price: $1.71
Moelis rates ((BGL)) as Upgrade to Buy from Hold (1) –
Moelis believes Bellevue Gold could be hedge free in 12 months’ time, which is likely to be a possible drain on 2026 cash flow compared to the previous scenario, but higher prices and better production could result in a rise in cash of around $170m, with a further circa 60koz Au deliveries from January 2027 to March 2026.
Starting January 1 2027, the gold producer could be possibly selling 100% of its production into a spot price environment, generating over $900m in annual revenue.
The broker upgrades the stock to Buy from Hold, with a rise in target price to $2 from $1.35.
This report was published on December 19, 2025.
Target price is $2.00 Current Price is $1.71 Difference: $0.29
If BGL meets the Moelis target it will return approximately 17% (excluding dividends, fees and charges).
Current consensus price target is $1.65, suggesting downside of -3.5%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 4.20 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 40.71.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 12.1, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 14.1.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents.
How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 18.6, implying annual growth of 53.7%.
Current consensus DPS estimate is 3.0, implying a prospective dividend yield of 1.8%.
Current consensus EPS estimate suggests the PER is 9.2.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
BOE BOSS ENERGY LIMITED
Uranium – Overnight Price: $1.32
Canaccord Genuity rates ((BOE)) as Buy (1) –
Boss Energy has withdrawn its feasibility study for Honeymoon, with no production growth expected in FY27. The complexity and lower high-grade mineralisation will result in higher all in sustaining costs, Canaccord Genuity explains.
Management is working on a new feasibility study for completion in 3Q26, which will concentrate on a new “wide spaced” wellfield design which can potentially lower costs and accommodate lower grade zones to be developed and monetised.
Boss is on track to deliver its FY26 guidance of 1.6mlb for Honeymoon, with no production growth for FY27.
Post update, the analyst has lowered plateau production to 2Mlb and increased all in sustaining costs to $75/lb for FY27 onwards, with total production for Honeymoon retained at 24Mlb.
The target price is lowered to $2.25 from $3.50, with a Speculative Buy rating retained.
This report was published on December 18, 2025.
Target price is $2.25 Current Price is $1.32 Difference: $0.93
If BOE meets the Canaccord Genuity target it will return approximately 70% (excluding dividends, fees and charges).
Current consensus price target is $1.91, suggesting upside of 44.5%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 8.38 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.75.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 20.4, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 6.5.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 20.57 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 6.42.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 34.1, implying annual growth of 67.2%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 3.9.
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
MPW METAL POWDER WORKS LIMITED
Overnight Price: $2.03
Canaccord Genuity rates ((MPW)) as Speculative Buy (1) –
Following an initiation of coverage of Metal Powder Works in October, Canaccord Genuity has maintained its Speculative Buy rating and $4.10 target price.
The company signed a powder partnership with Austal’s ((ASB)) US arm to supply metal powder for cold-spray additive manufacturing in US Navy shipbuilding.
The broker notes near-term revenue is immaterial pending 18–24 month qualification, but testing has begun toward a future offtake.
Operational momentum is building with an expanded sales team, in-sourced tooling, and next-gen commissioning due 1Q26.
Near-term revenue upside is most visible in laser cladding, while broader PM (powder metallurgy) and AM (additive manufacturing) customers remain in testing phases that could convert to recurring orders.
The broker believes the DirectPowder process underpins a structural cost advantage, supporting its 2028 target of 800t. The broker has modelled a conservative 254t and $31m revenue, and $7m EBITDA by FY28.
This report was published on December 17, 2025.
Target price is $4.10 Current Price is $2.03 Difference: $2.07
If MPW meets the Canaccord Genuity target it will return approximately 102% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 3.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 67.67.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 2.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 101.50.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
NWL NETWEALTH GROUP LIMITED
Wealth Management & Investments – Overnight Price: $26.47
Canaccord Genuity rates ((NWL)) as Buy (1) –
Canaccord Genuity reiterates its Buy rating on Netwealth Group, with a lower target price of $33.90 from $36.30, following an agreement with ASIC to pay -$110m in compensation to members impacted by First Guardian funding via a mix of cash and debt.
The analyst believes the decision should support sentiment towards the platform in terms of goodwill and trust, with a minimal negative financial impact.
Management confirmed its FY26 guidance for net flows to “not materially differ from FY25”.
The analyst lowers EPS forecasts by -2.4% for FY26 and -3.1% for FY27.
This report was published on December 18, 2025.
Target price is $33.90 Current Price is $26.47 Difference: $7.43
If NWL meets the Canaccord Genuity target it will return approximately 28% (excluding dividends, fees and charges).
Current consensus price target is $33.35, suggesting upside of 26.0%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 42.00 cents and EPS of 55.00 cents.
At the last closing share price the estimated dividend yield is 1.59%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 48.13.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 54.8, implying annual growth of 15.1%.
Current consensus DPS estimate is 43.8, implying a prospective dividend yield of 1.7%.
Current consensus EPS estimate suggests the PER is 48.3.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 52.00 cents and EPS of 65.00 cents.
At the last closing share price the estimated dividend yield is 1.96%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 40.72.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 64.5, implying annual growth of 17.7%.
Current consensus DPS estimate is 51.6, implying a prospective dividend yield of 1.9%.
Current consensus EPS estimate suggests the PER is 41.0.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
PLY PLAYSIDE STUDIOS LIMITED
Gaming – Overnight Price: $0.26
Canaccord Genuity rates ((PLY)) as Buy (1) –
Playside Studios announced a positive update, according to Canaccord Genuity, with 1H26 guidance of revenue $19-$20m versus the analyst’s forecast at $17m, with a skew to 2H26, including the launch of Mouse P.I. for Hire in March.
Positively, cost savings are proceeding ahead of expectations with -$6m versus -$4 to -$5m cost outs initially, which should support 1H26 earnings (EBITDA) of $8m-$10m.
Canaccord Genuity reiterates the Buy rating and 60c target price.
This report was published on December 18, 2025.
Target price is $0.60 Current Price is $0.26 Difference: $0.34
If PLY meets the Canaccord Genuity target it will return approximately 131% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 0.06 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 433.33.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 20.00.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
PWR PETER WARREN AUTOMOTIVE HOLDINGS LIMITED
Automobiles & Components – Overnight Price: $1.83
Moelis rates ((PWR)) as Buy (1) –
Peter Warren Automotive announced the acquisition of Wakeling Automotive for $28m, including 30 dealerships and 16 brands.
Moelis notes the addition will expand the geographic footprint, including operations across the Macarthur region as well as Wollongong, Shell Harbour and Moss Vale.
Additional brands include Hyundai, Kia, GWM, Chery, Omoda, and more. Wakeling is a 40-year old family business with around 370 employees.
The analyst lifts EPS forecasts by 3.5% for FY26 and 9.5% for FY27. The deal is subject to ACCC and OEM approvals.
Buy rating maintained with a rise in target to $2.43.
This report was published on December 19, 2025.
Target price is $2.43 Current Price is $1.83 Difference: $0.595
If PWR meets the Moelis target it will return approximately 32% (excluding dividends, fees and charges).
Current consensus price target is $2.08, suggesting upside of 13.5%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 7.80 cents and EPS of 13.00 cents.
At the last closing share price the estimated dividend yield is 4.25%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 14.12.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 11.8, implying annual growth of 67.9%.
Current consensus DPS estimate is 7.7, implying a prospective dividend yield of 4.2%.
Current consensus EPS estimate suggests the PER is 15.6.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 9.30 cents and EPS of 15.40 cents.
At the last closing share price the estimated dividend yield is 5.07%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 11.92.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 16.0, implying annual growth of 35.6%.
Current consensus DPS estimate is 10.2, implying a prospective dividend yield of 5.6%.
Current consensus EPS estimate suggests the PER is 11.5.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
SGLLV RICEGROWERS LIMITED
Food, Beverages & Tobacco – Overnight Price: $16.14
Research as a Service (RaaS) rates ((SGLLV)) as No Rating (-1) –
Ricegrowers’ 1H26 adjusted net profit was up 11.5% y/y and slightly topped Research as a Service (RaaS)’ expectations, helped by a lower tax rate.
Net debt fell to $169m, the lowest since Oct-2021, and cash conversion was strong, with a 20c interim dividend. Revenue slipped -3.1% as weaker Pacific Islands weren’t fully offset by strength in US/Middle East CPG, Toscano bakery and bulk animal feed.
The analyst is cautious on a potentially much smaller Riverina crop in 2026 that will impact FY27 sale, and assumes a -$10m one-off overhead under-recovery, but lower tax and debt.
Valuation $19.10.
Research as a Service (RaaS) research doesn’t carry any targets, ratings or recommendations. Investors can draw conclusions from valuations and commentary.
This report was published on December 22, 2025.
Target price is $19.10 Current Price is $16.14 Difference: $2.96
If SGLLV meets the Research as a Service (RaaS) target it will return approximately 18% (excluding dividends, fees and charges).
The company’s fiscal year ends in April.
Forecast for FY26:
Research as a Service (RaaS) forecasts a full year FY26 dividend of 70.00 cents and EPS of 122.00 cents.
At the last closing share price the estimated dividend yield is 4.34%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.23.
Forecast for FY27:
Research as a Service (RaaS) forecasts a full year FY27 dividend of 75.00 cents and EPS of 112.00 cents.
At the last closing share price the estimated dividend yield is 4.65%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 14.41.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
TLX TELIX PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $11.94
Canaccord Genuity rates ((TLX)) as Buy (1) –
Canaccord Genuity continues to rate Telix Pharmaceuticals as Buy wth a $28.50 target price while addressing the “topical” TLX591 asset with a safety read out anticipated next year.
The broker attributes the delay in ProstACT GLOBAL Part 1 reporting to the docetaxel 10 cohort being the rate limiting step, given TLX591 must be dosed first and docetaxel is given later with follow up required after the second cycle.
US sites likely drove most enrollment, but US prescribing preferences favour androgen receptor pathway inhibitors, which may have slowed progress. Canaccord believes docetaxel was included to support a globally relevant mCRPC label and to avoid crossover, which can confound overall survival in comparator trials.
The analyst expects safety to be manageable given sequential dosing and will watch for any new safety signals and severe haematologic toxicity.
This report was published on December 19, 2025.
Target price is $28.50 Current Price is $11.94 Difference: $16.56
If TLX meets the Canaccord Genuity target it will return approximately 139% (excluding dividends, fees and charges).
Current consensus price target is $27.20, suggesting upside of 127.8%(ex-dividends)
The company’s fiscal year ends in December.
Forecast for FY25:
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus 13.27 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 89.98.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is -2.0, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 4.91 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 243.18.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 8.4, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 142.1.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don’t have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.
<span style="
Click to view our Glossary of Financial Terms
CHARTS
For more info SHARE ANALYSIS: 3DA - AMAERO LIMITED
For more info SHARE ANALYSIS: ACW - ACTINOGEN MEDICAL LIMITED
For more info SHARE ANALYSIS: AHL - ADRAD HOLDINGS LIMITED
For more info SHARE ANALYSIS: ARF - ARENA REIT
For more info SHARE ANALYSIS: ASB - AUSTAL LIMITED
For more info SHARE ANALYSIS: ATA - ATTURRA LIMITED
For more info SHARE ANALYSIS: AZY - ANTIPA MINERALS LIMITED
For more info SHARE ANALYSIS: BGL - BELLEVUE GOLD LIMITED
For more info SHARE ANALYSIS: BOE - BOSS ENERGY LIMITED
For more info SHARE ANALYSIS: MPW - METAL POWDER WORKS LIMITED
For more info SHARE ANALYSIS: NWL - NETWEALTH GROUP LIMITED
For more info SHARE ANALYSIS: PLY - PLAYSIDE STUDIOS LIMITED
For more info SHARE ANALYSIS: PWR - PETER WARREN AUTOMOTIVE HOLDINGS LIMITED
For more info SHARE ANALYSIS: TLX - TELIX PHARMACEUTICALS LIMITED
For more info SHARE ANALYSIS: TTT - TITOMIC LIMITED